Subtopic Deep Dive
Lentiviral Vectors in Hematopoietic Stem Cell Therapy
Research Guide
What is Lentiviral Vectors in Hematopoietic Stem Cell Therapy?
Lentiviral vectors in hematopoietic stem cell therapy use self-inactivating HIV-based backbones to achieve stable gene integration and long-term expression in HSCs for treating immunodeficiencies and hemoglobinopathies.
This approach transduces CD34+ HSCs ex vivo for autologous transplantation, enabling cures for diseases like SCID, Wiskott-Aldrich syndrome (WAS), and metachromatic leukodystrophy (MLD). Key studies report clinical benefits with over 1000 citations each (Biffi et al., 2013; Aiuti et al., 2013). Approximately 20 foundational papers from 1999-2014 established SIN lentiviral safety and efficacy in NOD/SCID mouse models (Miyoshi et al., 1999).
Why It Matters
Lentiviral HSC gene therapy cured MLD patients with restored myelination and immune function (Biffi et al., 2013, 1181 citations). WAS patients achieved platelet normalization and infection resistance post-therapy (Aiuti et al., 2013, 1024 citations; Boztug et al., 2010, 532 citations). Sickle cell disease treatment corrected β-globin expression in transfused HSCs (Ribeil et al., 2017, 657 citations). These outcomes expanded applications to 20+ trials for hemoglobinopathies, reducing reliance on allogeneic transplants.
Key Research Challenges
Genotoxicity from Insertional Mutagenesis
Lentiviral integration near proto-oncogenes risks clonal dominance and leukemia, as observed in early gamma-retroviral trials. SIN backbones and insulators mitigate but require long-term monitoring (Milone and O’Doherty, 2018). Biffi et al. (2013) tracked integration sites in MLD patients over 5 years.
Low HSC Transduction Efficiency
CD34+ cells resist transduction without prolonged cytokine exposure, impairing repopulating potential. HIV vectors improved engraftment in NOD/SCID mice but yields remain below 50% (Miyoshi et al., 1999). Demaison et al. (2002) enhanced expression using SFFV promoters.
Immune Responses to Vector Components
Residual HIV elements trigger adaptive immunity, reducing transgene persistence post-infusion. Clinical trials report neutralizing antibodies in 20-30% of patients (Aiuti et al., 2013). Promoter refinements minimize expression silencing (Bulcha et al., 2021).
Essential Papers
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
Hongyi Li, Yang Yang, Weiqi Hong et al. · 2020 · Signal Transduction and Targeted Therapy · 1.6K citations
Abstract Based on engineered or bacterial nucleases, the development of genome editing technologies has opened up the possibility of directly targeting and modifying genomic sequences in almost all...
Viral vector platforms within the gene therapy landscape
Jote Bulcha, Yi Wang, Hong Ma et al. · 2021 · Signal Transduction and Targeted Therapy · 1.2K citations
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Alessandra Biffi, Eugenio Montini, Laura Lorioli et al. · 2013 · Science · 1.2K citations
Next-Generation Gene Therapy Few disciplines in contemporary clinical research have experienced the high expectations directed at the gene therapy field. However, gene therapy has been challenging ...
Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome
Alessandro Aiuti, Luca Biasco, Samantha Scaramuzza et al. · 2013 · Science · 1.0K citations
Next-Generation Gene Therapy Few disciplines in contemporary clinical research have experienced the high expectations directed at the gene therapy field. However, gene therapy has been challenging ...
Clinical use of lentiviral vectors
Michael C. Milone, Una O’Doherty · 2018 · Leukemia · 828 citations
Gene Therapy in a Patient with Sickle Cell Disease
Jean‐Antoine Ribeil, Salima Hacein‐Bey‐Abina, Emmanuel Payen et al. · 2017 · New England Journal of Medicine · 657 citations
Sickle cell disease results from a homozygous missense mutation in the β-globin gene that causes polymerization of hemoglobin S. Gene therapy for patients with this disorder is complicated by the c...
Transduction of Human CD34 <sup>+</sup> Cells That Mediate Long-Term Engraftment of NOD/SCID Mice by HIV Vectors
Hiroyuki Miyoshi, Kevin M. Smith, Donald E. Mosier et al. · 1999 · Science · 632 citations
Efficient gene transfer into human hematopoietic stem cells (HSCs) is an important goal in the study of the hematopoietic system as well as for gene therapy of hematopoietic disorders. A lentiviral...
Reading Guide
Foundational Papers
Start with Miyoshi et al. (1999, Science, 632 citations) for initial HIV vector proof in NOD/SCID mice, then Biffi et al. (2013) and Aiuti et al. (2013) for first clinical cures in MLD and WAS.
Recent Advances
Study Bulcha et al. (2021, 1204 citations) for vector platforms and Ribeil et al. (2017, NEJM, 657 citations) for sickle cell applications.
Core Methods
Core techniques include SIN backbone design, VSV-G enveloping, SFFV promoters, and integration site analysis via LAM-PCR (Milone and O’Doherty, 2018).
How PapersFlow Helps You Research Lentiviral Vectors in Hematopoietic Stem Cell Therapy
Discover & Search
Research Agent uses searchPapers with query 'lentiviral HSC transduction WAS MLD' to retrieve Biffi et al. (2013) (1181 citations), then citationGraph maps 500+ downstream studies on genotoxicity. exaSearch uncovers unpublished trial data; findSimilarPapers links Miyoshi et al. (1999) to 1999-2021 vector evolution.
Analyze & Verify
Analysis Agent applies readPaperContent to Aiuti et al. (2013) for integration site maps, verifiesResponse with CoVe against Milone and O’Doherty (2018) for genotoxicity rates, and runPythonAnalysis on transduction efficiencies (e.g., pandas analysis of CD34+ yields from Demaison et al., 2002). GRADE grading scores Biffi et al. (2013) evidence as high for clinical efficacy.
Synthesize & Write
Synthesis Agent detects gaps in long-term safety data post-2018 via contradiction flagging across Ribeil et al. (2017) and Bulcha et al. (2021). Writing Agent uses latexEditText for methods sections, latexSyncCitations to bibtex Aiuti et al. (2013), latexCompile for full manuscripts, and exportMermaid for transduction workflow diagrams.
Use Cases
"Analyze transduction efficiencies in lentiviral HSC trials for WAS"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas plots of %CD34+ from Aiuti et al. 2013 vs Miyoshi et al. 1999) → matplotlib efficiency graphs.
"Write LaTeX review on lentiviral vectors for MLD gene therapy"
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro) → latexSyncCitations (Biffi et al. 2013) → latexCompile → PDF with integrated figures.
"Find code for lentiviral integration site analysis"
Research Agent → paperExtractUrls (Demaison et al. 2002) → paperFindGithubRepo → githubRepoInspect → exportCsv of integration hotspots.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'lentiviral HSC genotoxicity', structures report with GRADE-scored sections from Biffi et al. (2013) and Aiuti et al. (2013). DeepScan applies 7-step CoVe to verify Ribeil et al. (2017) sickle cell outcomes against Bulcha et al. (2021). Theorizer generates hypotheses on insulator designs from Miyoshi et al. (1999) citationGraph.
Frequently Asked Questions
What defines lentiviral vectors in HSC therapy?
Self-inactivating HIV-1 vectors transduce quiescent CD34+ HSCs for stable integration without cell division (Miyoshi et al., 1999).
What methods improve transduction efficiency?
VSV-G pseudotyping and SFFV promoters enable high-level expression in repopulating cells (Demaison et al., 2002).
What are key papers?
Biffi et al. (2013, Science, 1181 citations) for MLD; Aiuti et al. (2013, Science, 1024 citations) for WAS.
What open problems remain?
Reducing insertional mutagenesis risks and scaling manufacturing for hemoglobinopathies (Milone and O’Doherty, 2018).
Research Virus-based gene therapy research with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Lentiviral Vectors in Hematopoietic Stem Cell Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers
Part of the Virus-based gene therapy research Research Guide